171 related articles for article (PubMed ID: 11100886)
1. The role of human and viral cytokines in the pathogenesis of multiple myeloma.
Berenson JR; Sjak-Shie NN; Vescio RA
Semin Cancer Biol; 2000 Oct; 10(5):383-91. PubMed ID: 11100886
[TBL] [Abstract][Full Text] [Related]
2. Role of cytokines in pathogenesis of endometriosis.
Barcz E; Kamiński P; Marianowski L
Med Sci Monit; 2000; 6(5):1042-6. PubMed ID: 11208452
[TBL] [Abstract][Full Text] [Related]
3. Cytokines and signal transduction.
Hideshima T; Podar K; Chauhan D; Anderson KC
Best Pract Res Clin Haematol; 2005; 18(4):509-24. PubMed ID: 16026734
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma and human immunodeficiency virus-1 (HIV-1) infection.
Yee TT; Murphy K; Johnson M; Abdalla SH; Patton GS; Lee CA; Mehta AB
Am J Hematol; 2001 Feb; 66(2):123-5. PubMed ID: 11421291
[TBL] [Abstract][Full Text] [Related]
5. Etiology of multiple myeloma: what's new.
Berenson JR
Semin Oncol; 1999 Oct; 26(5 Suppl 13):2-9. PubMed ID: 10528889
[TBL] [Abstract][Full Text] [Related]
6. Paraproteinaemias: pathophysiology.
Samson D
Schweiz Med Wochenschr; 2000 Nov; 130(44):1643-8. PubMed ID: 11103434
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow angiogenesis in multiple myeloma: closing in on the loop.
Molina JR; Rajkumar SV
Haematologica; 2003 Feb; 88(2):122-4. PubMed ID: 12604399
[No Abstract] [Full Text] [Related]
8. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
9. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
Gadó K; Domján G; Hegyesi H; Falus A
Cell Biol Int; 2000; 24(4):195-209. PubMed ID: 10816321
[TBL] [Abstract][Full Text] [Related]
10. HHV-8 and multiple myeloma.
Berenson JR; Vescio RA
Pathol Biol (Paris); 1999 Feb; 47(2):115-8. PubMed ID: 10192878
[TBL] [Abstract][Full Text] [Related]
11. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease.
Flyvbjerg A
Diabetologia; 2000 Oct; 43(10):1205-23. PubMed ID: 11079738
[TBL] [Abstract][Full Text] [Related]
12. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
13. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
14. [Functions and the regulation of cytokines and growth factors in the thrombotic event of arteries and veins].
Harada H; Kakefuda T; Nouga K
Nihon Rinsho; 1999 Jul; 57(7):1497-501. PubMed ID: 10429447
[TBL] [Abstract][Full Text] [Related]
15. Human herpesvirus 8 genome is not found in whole bone marrow core biopsy specimens of patients with plasma cell dyscrasias.
Drabick JJ; Davis BJ; Lichy JH; Flynn J; Byrd JC
Ann Hematol; 2002 Jun; 81(6):304-7. PubMed ID: 12107558
[TBL] [Abstract][Full Text] [Related]
16. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
[TBL] [Abstract][Full Text] [Related]
17. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis in multiple myeloma.
Jakob C; Sterz J; Zavrski I; Heider U; Kleeberg L; Fleissner C; Kaiser M; Sezer O
Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
[TBL] [Abstract][Full Text] [Related]
19. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
Podar K; Richardson PG; Chauhan D; Anderson KC
Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
[TBL] [Abstract][Full Text] [Related]
20. Initiation and maintenance of multiple myeloma.
Berenson JR; Bergsagel PL; Munshi N
Semin Hematol; 1999 Jan; 36(1 Suppl 3):9-13. PubMed ID: 9989483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
